Form 4: Eric Venker Executes Roivant Stock Option Exercise

Roivant Sciences President Eric Venker exercised 200,000 stock options and sold the resulting shares on April 20, 2026.

Summary

• Eric Venker, President of Roivant Sciences and CEO of Immunovant, exercised 200,000 stock options at a strike price of $3.85.
• Following the exercise, the acquired shares were sold at a weighted average price of $29.59 per share.
• The transactions were conducted pursuant to a pre-arranged Rule 10b5-1 trading plan.
• Post-transaction, Venker retains beneficial ownership of 1,647,546 common shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; it is a routine exercise of vested equity under a pre-established plan, which is common for corporate executives.

Positives

• The transaction was executed under a pre-planned Rule 10b5-1 trading plan, indicating a systematic approach to equity management rather than reactive selling.
• The executive maintains a significant remaining stake of 1,647,546 shares, demonstrating continued alignment with shareholder interests.

Negatives

• The sale of 200,000 shares represents a reduction in the executive's direct holdings.

Risks

• Future share price volatility could impact the value of the executive's remaining 1,647,546 shares.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Management Comments

• The reporting person has committed to providing full details regarding the specific prices of the shares sold within the $29.33 to $29.88 range upon request.

Industry Context

StockSavvy.ai notes that executive stock sales under Rule 10b5-1 plans are standard practice in the biotech sector, allowing leadership to diversify holdings while mitigating concerns regarding non-public information usage.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for C-suite executives at publicly traded pharmaceutical companies to manage equity compensation.

Stakeholder Impact

• Shareholders should view this as a routine liquidity event for an executive, not necessarily indicative of a change in company outlook.

Next Steps

• No further actions or milestones were disclosed in this filing.

Key Dates

Keywords

Roivant Sciences, ROIV, Insider Trading, Form 4, Eric Venker, Stock Options, Biotech